168 related articles for article (PubMed ID: 3925267)
1. Beclobrinic acid--a new hypolipidemic agent--inhibits in vitro human platelet activation by blocking prostaglandin synthesis.
Anwer K; Gabis J; Romstedt K; Gojer C; Huzoor-Akbar
Life Sci; 1985 Jul; 37(1):63-70. PubMed ID: 3925267
[TBL] [Abstract][Full Text] [Related]
2. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam.
Romstedt K; Huzoor-Akbar
Thromb Res; 1985 May; 38(4):361-74. PubMed ID: 2990062
[TBL] [Abstract][Full Text] [Related]
3. Potent antiplatelet effects of cyclic clofibric acid (CPIB) analogs on human platelets.
Romstedt KJ; Kim SU; Witiak DT; Newman HA; Feller DR
Thromb Res; 1989 May; 54(4):289-99. PubMed ID: 2503906
[TBL] [Abstract][Full Text] [Related]
4. Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analogue.
Witiak DT; Kim SK; Romstedt K; Newman HA; Feller DR
J Med Chem; 1986 Nov; 29(11):2170-4. PubMed ID: 3097315
[TBL] [Abstract][Full Text] [Related]
5. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
6. Effect of phorbol 12-myristate 13-acetate (PMA) on agonist-induced arachidonate release and 5-hydroxytryptamine secretion in human platelets. Dependence of effects on agonist type and time of incubation with PMA.
Krishnamurthi S; Joseph S; Kakkar VV
Biochim Biophys Acta; 1987 Mar; 927(3):429-36. PubMed ID: 3101746
[TBL] [Abstract][Full Text] [Related]
7. Potentiating effects of clofibrate on prostaglandin-dependent and -independent pathways of human platelet activation: evidence for involvement of cyclic AMP.
Huzoor-Akbar ; Witiak DT; Newman HA; Fertel RH; Feller DR
Biochem Pharmacol; 1982 Jun; 31(11):2125-8. PubMed ID: 6288050
[TBL] [Abstract][Full Text] [Related]
8. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the role of arachidonic acid in platelet function and mechanisms for suppression of prostaglandin biosynthesis.
Huzoor-Akbar ; Ardlie NG
Br J Haematol; 1978 May; 39(1):71-81. PubMed ID: 666979
[No Abstract] [Full Text] [Related]
10. Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.
Minkes M; Stanford N; Chi MM; Roth GJ; Raz A; Needleman P; Majerus PW
J Clin Invest; 1977 Mar; 59(3):449-54. PubMed ID: 190267
[TBL] [Abstract][Full Text] [Related]
11. Platelet desensitization by arachidonic acid is associated with the suppression of endoperoxide/thromboxane A2 binding to the membrane receptor.
Sato T; Hashizume T; Nakao K; Akiba S; Fujii T
Biochim Biophys Acta; 1989 Aug; 992(2):168-73. PubMed ID: 2503041
[TBL] [Abstract][Full Text] [Related]
12. Effects of vinblastine on malondialdehyde formation, serotonin release and aggregation in human platelets.
Brammer JP; Kerecsen L; Maguire MH
Eur J Pharmacol; 1982 Jul; 81(4):577-85. PubMed ID: 6811295
[TBL] [Abstract][Full Text] [Related]
13. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
Brammer JP; Maguire MH
Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR
Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894
[TBL] [Abstract][Full Text] [Related]
15. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
17. 3-Deazaadenosine and L-homocysteine inhibit human platelet activation induced by arachidonic acid, U46619 and phospholipase C.
Huzoor-Akbar ; Romstedt K
Thromb Res; 1984 Nov; 36(4):369-76. PubMed ID: 6098050
[No Abstract] [Full Text] [Related]
18. Inhibitory effect of stearidonic acid (18:4 n-3) on platelet aggregation and arachidonate oxygenation.
Kockmann V; Spielmann D; Traitler H; Lagarde M
Lipids; 1989 Dec; 24(12):1004-7. PubMed ID: 2559279
[TBL] [Abstract][Full Text] [Related]
19. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets.
di Minno G; Bertelé V; Bianchi L; Barbieri B; Cerletti C; Dejana E; de Gaetano G; Silver MJ
Thromb Haemost; 1981 Apr; 45(2):103-6. PubMed ID: 6266066
[TBL] [Abstract][Full Text] [Related]
20. The action of halofenate on platelet shape change and prostaglandin synthesis.
Favis GR; Colman RW
J Lab Clin Med; 1978 Jul; 92(1):45-52. PubMed ID: 659964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
